bet inhibitor incb057643
bet inhibitor incb057643: 4 clinical trials tracked.
bet inhibitor incb057643 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about bet inhibitor incb057643, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (4)
Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of INCB057643
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Primary endpoint: Number of treatment-emergent adverse events
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Primary endpoint: Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAE's).